心鈉肽(ANP)檢測試劑盒(酶聯(lián)免疫吸附試驗法)
ELISA Kit for Atrial Natriuretic Peptide (ANP)
ANH; ANF; CDD; Atrial Natriuretic Factor; Atrial Natriuretic Hormone; Atriopeptin; Cardionatrine; Cardiodilatin
- 編號CEA225Eq
- 物種Equus caballus; Equine (Horse,馬) 相同的名稱,不同的物種。
- 實驗方法競爭抑制
- 反應(yīng)時長2h
- 檢測范圍24.69-2,000pg/mL
- 靈敏度最小可檢測劑量小于等于9.09pg/m.
- 樣本類型serum, plasma, tissue homogenates and other biological fluids
- 下載 英文說明書 中文說明書
- 規(guī)格 48T96T 96T*5 96T*10 96T*100
- 價格 ¥ 3251 ¥ 4644 ¥ 20898 ¥ 39474 ¥ 325080
- 欲了解實際交易價格和更多情況,請與當(dāng)?shù)亟?jīng)銷商聯(lián)系!
特異性
本試劑盒用于檢測心鈉肽(ANP),經(jīng)檢測與其它相似物質(zhì)無明顯交叉反應(yīng)。
由于受到技術(shù)及樣本來源的限制,不可能完成對所有相關(guān)或相似物質(zhì)交叉反應(yīng)檢測,因此本試劑盒有可能與未經(jīng)檢測的其它物質(zhì)有交叉反應(yīng)。
回收率
分別于定值血清及血漿樣本中加入一定量的心鈉肽(ANP)(加標(biāo)樣品),重復(fù)測定并計算其均值,回收率為測定值與理論值的比率。
樣本 | 回收率范圍(%) | 平均回收率(%) |
serum(n=5) | 83-102 | 95 |
EDTA plasma(n=5) | 97-104 | 101 |
heparin plasma(n=5) | 87-97 | 90 |
精密度
精密度用樣品測定值的變異系數(shù)CV表示。CV(%) = SD/mean×100
批內(nèi)差:取同批次試劑盒對低、中、高值定值樣本進(jìn)行定量檢測,每份樣本連續(xù)測定20 次,分別計算不同濃度樣本的平均值及SD值。
批間差:選取3個不同批次的試劑盒分別對低、中、高值定值樣本進(jìn)行定量測定,每個樣本使用同一試劑盒重復(fù)測定8次,分別計算不同濃度樣本的平均值及SD值。
批內(nèi)差: CV<10%
批間差: CV<12%
線性
在定值血清及血漿樣本內(nèi)加入適量的心鈉肽(ANP),并倍比稀釋成1:2,1:4,1:8,1:16的待測樣本,線性范圍即為稀釋后樣本中心鈉肽(ANP)含量的測定值與理論值的比率。
樣本 | 1:2 | 1:4 | 1:8 | 1:16 |
serum(n=5) | 90-101% | 94-105% | 88-96% | 97-104% |
EDTA plasma(n=5) | 85-93% | 82-102% | 78-91% | 86-103% |
heparin plasma(n=5) | 94-102% | 99-105% | 86-94% | 93-101% |
穩(wěn)定性
經(jīng)測定,試劑盒在有效期內(nèi)按推薦溫度保存,其活性降低率小于5%。
為減小外部因素對試劑盒破壞前后檢測值的影響,實驗室的環(huán)境條件需盡量保持一致,尤其是實驗室內(nèi)溫度、濕度及溫育條件。其次由同一實驗員來進(jìn)行操作可減少人為誤差。
實驗流程
1. 實驗前標(biāo)準(zhǔn)品、試劑及樣本的準(zhǔn)備;
2. 加樣(標(biāo)準(zhǔn)品及樣本)50µL,
加入50µL檢測液A(臨用前配制);
37°C溫育1小時。
3. 洗板3次;
4. 加檢測溶液B100µL,37°C孵育30分鐘;
5. 洗板5次;
6. 加TMB底物90µL,37°C孵育10-20分鐘;
7. 加終止液50µL,立即450nm讀數(shù)。
實驗原理
本試劑盒應(yīng)用競爭抑制酶聯(lián)免疫分析法測定標(biāo)本中待測物質(zhì)水平。將心鈉肽(ANP)單克隆抗體包被微孔板,制成固相載體,往包被抗體的微孔中同時加入生物素標(biāo)記的抗原和待測抗原(標(biāo)準(zhǔn)品或樣本),待測抗原與生物素標(biāo)記抗原對特異性抗體進(jìn)行競爭結(jié)合。溫育后經(jīng)洗滌去掉未結(jié)合物,然后加入HRP標(biāo)記的親和素,經(jīng)過溫育和徹底洗滌后加入底物TMB顯色。TMB在過氧化物酶的催化下轉(zhuǎn)化成藍(lán)色,并在酸的作用下轉(zhuǎn)化成最終的黃色。待測標(biāo)本濃度越高,標(biāo)記抗原和抗體的結(jié)合就越受到抑制,顯色愈淺。顯色的深淺與酶量呈正相關(guān),而與樣品中待測物質(zhì)含量呈負(fù)相關(guān)。用酶標(biāo)儀在450nm波長下測定吸光度(O.D.值),計算樣品濃度。
相關(guān)產(chǎn)品
編號 | 適用物種:Equus caballus; Equine (Horse,馬) | 應(yīng)用(僅供研究使用,不用于臨床診斷!) |
RPA225Eq01 | 心鈉肽(ANP)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
CPA225Eq21 | 心鈉肽(ANP)卵白蛋白偶聯(lián)物 | Immunogen; SDS-PAGE; WB. |
PAA225Eq01 | 心鈉肽(ANP)多克隆抗體 | WB; IHC; ICC; IP. |
PAA225Eq08 | 心鈉肽(ANP)多克隆抗體 | WB; IHC; ICC; IP. |
MAA225Eq21 | 心鈉肽(ANP)單克隆抗體 | WB; IHC; ICC; IP. |
CEA225Eq | 心鈉肽(ANP)檢測試劑盒(酶聯(lián)免疫吸附試驗法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
LMA225Eq | 心鈉肽(ANP)等多因子檢測試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. |
參考文獻(xiàn)
雜志 | 參考文獻(xiàn) |
8 | Volume Status and Diuretic Therapy in Systolic Heart Failure and the Detection of Early Abnormalities in Renal and Tubular Function [PubMed: 21616283] |
Basic Research in Cardiology | Release of atrial natriuretic peptide precedes shedding of the endothelial glycocalyx equally in patients undergoing on- and off-pump coronary artery bypass surgery [PubMed: 21769675] |
Neuropsychobiology. | Atrial natriuretic Peptide, arginine vasopressin Peptide and cortisol serum levels in opiate-dependent patients [PubMed: 23406607] |
European addiction research | Alcohol-induced changes in methylation status of individual CpG sites, and serum levels of vasopressin and atrial natriuretic peptide in alcohol-dependent patients during detoxification treatment. [Pubmed: 24356727] |
Crit Care. | Hypervolemia increases release of atrial natriuretic peptide and shedding of the endothelial glycocalyx [Pubmed:25497357] |
Diabet Med.? | Sodium-glucose co-transporter-2 inhibitors suppress atrial natriuretic peptide secretion in patients with newly diagnosed Type 2 diabetes. [Pubmed:26927445] |
J Ethnopharmacol | Danhong injection attenuates isoproterenol-induced cardiac hypertrophy by reCavia (Guinea pig )lating p38 and NF-κb pathway [Pubmed:26970569] |
Journal of Babylon University/Pure and Applied Sciences | Blood Pressure and Atrial Natriuretic Peptide (ANP) Levels in Patients with Autosomal Dominant Polycystic Kidney Disease. [papers:uobj_paper_2016_62613672.pdf] |
PLoS One | Enhanced heart failure, mortality and renin activation in female mice with experimental dilated cardiomyopathy [pubmed:29240788] |
Drug Delivery | Ginsenoside Rg3 micelles mitigate doxorubicin-induced cardiotoxicity and enhance its anticancer efficacy. [pubmed:29063791] |
Elife | SIRT2 deacetylase regulates the activity of GSK3 isoforms independent of inhibitory phosphorylation [Pubmed:29504933] |
Science?of the?Total?Environment | Co-exposure of silica nanoparticles and methylmercury induced cardiac toxicity and [Pubmed:29727991] |
The Journal of Biological Chemistry | Toll-like receptor 2 deficiency hyperactivates the FoxO1 transcription factor and induces aging-associated cardiac dysfunction in mice [Pubmed:29929978] |
Pediatric Cardiology | Determinants of Increased Aortic Diameters in Young Normotensive Patients With Turner Syndrome Without Structural Heart Disease [Pubmed:29392348] |
FASEB?Journal | Signature-oriented investigation of the efficacy of multicomponent drugs against heart failure [Pubmed: 30230922] |
Endokrynologia Polska | Endothelin-1 (ET-1), N-terminal fragment of proatrial natriuretic peptide (NTpro-ANP) and tumor necrosis factor alpha (TNF-α) in children with primary hypertension?… [Pubmed: 30359461] |
International Journal of Peptide Research and Therapeutics | ANP/NPRA Inhibits Epithelial-Mesenchymal Transition of Airway by Targeting Smad3 in Asthma [] |
Van Veterinary Journal | Relationship between Natriuretic Peptide Levels with Heart and Kidney Parameters in Rats with Chronic Renal Failure. [] |
Acta Pharmaceutica Sinica B | The poly (ADP-ribosyl) ation of BRD4 mediated by PARP1 promoted pathological cardiac hypertrophy [34094834] |
Peptides | Alarin moderated myocardial hypertrophy via inhibiting cyclic adenosine monophosphate/protein kinase A signaling pathway to attenuate autophagy [34624429] |
Peptides | Osteocrin alleviates cardiac hypertrophy via attenuating oxidative stress [Pubmed:35218795] |